Search

Your search keyword '"Doll, Helen"' showing total 726 results
Start Over Author "Doll, Helen"
726 results on '"Doll, Helen"'

1. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA‐AD™): a clinical outcome measure for the severity of atopic dermatitis

Author

Simpson, Eric L, Bissonnette, Robert, Paller, Amy S, King, Brett, Silverberg, Jonathan I, Reich, Kristian, Thyssen, Jacob P, Doll, Helen, Sun, Luna, DeLozier, Amy M, Nunes, Fabio P, and Eichenfield, Lawrence F

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Adult, Azetidines, Clinical Trials, Phase III as Topic, Dermatitis, Atopic, Humans, Outcome Assessment, Health Care, Purines, Pyrazoles, Reproducibility of Results, Severity of Illness Index, Sulfonamides, Oncology and Carcinogenesis, Dermatology & Venereal Diseases, Clinical sciences
Abstract

BackgroundThe validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) is a standardized severity assessment for use in clinical trials and registries for atopic dermatitis (AD).ObjectivesTo investigate the reliability, validity, responsiveness and within-patient meaningful change of the vIGA-AD.MethodsData were analysed from adult patients with moderate-to-severe AD in the BREEZE-AD1 (N = 624 patients; NCT03334396), BREEZE-AD2 (N = 615; NCT03334422) and BREEZE-AD5 (N = 440; NCT03435081) phase III baricitinib clinical studies.ResultsAcross studies, test-retest reliability for stable patients showed moderate-to-good agreement [range of Kappa values for Patient Global Impression of Severity-Atopic Dermatitis (PGI-S-AD), 0·516-0·639; for Eczema Area and Severity Index (EASI), 0·658-0·778]. Moderate-to-large correlations between vIGA-AD and EASI or body surface area (range at baseline, 0·497-0·736; Week 16, 0·716-0·893) supported convergent validity. Known-groups validity was demonstrated vs. EASI and PGI-S-AD (vIGA-AD for severe vs. moderate EASI categories at baseline, P

Published
2022

2. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis

Author

Silverberg, Jonathan I, DeLozier, Amy, Sun, Luna, Thyssen, Jacob P, Kim, Brian, Yosipovitch, Gil, Nunes, Fabio P, Gugiu, P Cristian, Doll, Helen A, and Eichenfield, Lawrence F

Subjects
Health Services and Systems, Public Health, Health Sciences, Pain Research, Neurosciences, Clinical Research, Chronic Pain, Adult, Dermatitis, Atopic, Humans, Pain, Psychometrics, Quality of Life, Reproducibility of Results, Severity of Illness Index, Sleep, Atopic dermatitis, Atopic dermatitis sleep scale, Convergent-divergent validity, Itch NRS, Numeric rating scale, Patient-reported outcome, Psychometric, Reliability, Responsiveness, Skin pain NRS, Validity, Public Health and Health Services, Health Policy & Services, Health services and systems, Public health
Abstract

BackgroundThe Itch Numeric Rating Scale (NRS), Skin Pain NRS, and Atopic Dermatitis Sleep Scale (ADSS) are self-administered patient-reported outcome (PRO) instruments developed to assess symptoms in patients with atopic dermatitis (AD). The objective of this study was to evaluate the psychometric properties (reliability, validity, and responsiveness) and interpretability thresholds of these PROs using data from three pivotal Phase 3 studies in adults.MethodsBREEZE-AD1, BREEZE-AD2, and BREEZE-AD5 evaluated the safety and efficacy of baricitinib in adults with moderate-to-severe AD. Clinician-reported outcomes and other PROs commonly assessed in patients with AD were used to estimate meaningful changes and evaluate test-retest reliability, convergent and divergent validity, known-groups validity, responsiveness, and meaningful change thresholds (MCTs) of the Itch NRS, Skin Pain NRS, and ADSS.ResultsThe test-retest reliability of the Itch NRS, Skin Pain NRS, and ADSS was evidenced by generally large intraclass correlation coefficients (> 0.7) in stable groups of patients between baseline and Week 1 and Weeks 4 and 8. Moderate-to-large correlations (r > 0.4) at baseline and Week 16 were generally observed between each measure and other PROs measuring the same concept, supporting convergent validity. Small-to-moderate correlations with clinician-reported outcomes demonstrated divergent validity. Each instrument was able to distinguish between known groups of disease severity as assessed using other indicators of AD severity. The responsiveness of the Itch NRS, Skin Pain NRS, and ADSS scales was demonstrated through significant differences in their change scores from baseline to Week 16 between categories of change in another PRO also from baseline to Week 16. Thresholds for interpreting meaningful change were estimated as - 4.0 for the 0-10 Itch and Skin Pain NRS items; - 1.25 for the 0-4 ADSS Items 1 and 3 and; - 1.50 for the 0-29 ADSS Item 2, these equivalent to moderate degrees of change.ConclusionsResults of this study demonstrate that the psychometric properties of the Itch NRS, Skin Pain NRS, and ADSS are good to excellent. These findings support the use of these instruments in daily assessment of AD symptoms in adults with moderate-to-severe AD. Trial registration ClinicalTrials.gov numbers: NCT03334396, NCT03334422, and NCT03435081.

Published
2021

4. Admission avoidance hospital at home

Author

Edgar, Kate, additional, Iliffe, Steve, additional, Doll, Helen A, additional, Clarke, Mike J, additional, Gonçalves-Bradley, Daniela C, additional, Wong, Eric, additional, and Shepperd, Sasha, additional

Published
2024
Full Text
View/download PDF

26. Mental Disorders among Adolescents in Juvenile Detention and Correctional Facilities: A Systematic Review and Metaregression Analysis of 25 Surveys

Author

Fazel, Seena, Doll, Helen, and Langstrom, Niklas

Abstract

The article presents a meta-analysis of all existing surveys on the prevalence of psychiatric morbidity in adolescents in juvenile detention and correctional facilities in order to assess the prevalence of mental disorders. Findings indicate adolescents in detention are 10 times more likely to suffer from psychosis than the general adolescent population.

Published
2008

27. Cost effectiveness of telehealth for patients with long term conditions (Whole Systems Demonstrator telehealth questionnaire study): nested economic evaluation in a pragmatic, cluster randomised controlled trial

Author

Whole System Demonstrator evaluation team, Henderson, Catherine, Knapp, Martin, Fernández, José-Luis, Beecham, Jennifer, Hirani, Shashivadan P, Cartwright, Martin, Rixon, Lorna, Beynon, Michelle, Rogers, Anne, Bower, Peter, Doll, Helen, Fitzpatrick, Ray, Steventon, Adam, Bardsley, Martin, Hendy, Jane, and Newman, Stanton P

Published
2013

28. Effect of telehealth on quality of life and psychological outcomes over 12 months (Whole Systems Demonstrator telehealth questionnaire study): nested study of patient reported outcomes in a pragmatic, cluster randomised controlled trial

Author

Whole Systems Demonstrator evaluation team, Cartwright, Martin, Hirani, Shashivadan P, Rixon, Lorna, Beynon, Michelle, Doll, Helen, Bower, Peter, Bardsley, Martin, Steventon, Adam, Knapp, Martin, Henderson, Catherine, Rogers, Anne, Sanders, Caroline, Fitzpatrick, Ray, Barlow, James, and Newman, Stanton P

Published
2013

49. Additional file 1 of Concept confirmation of the Treatment Administration Satisfaction Questionnaire (TASQ) in rare paroxysmal nocturnal hemoglobinuria

Author

Doll, Helen, Coşkun, Ufuk, Hartford, Chris, and Tomazos, Ioannis

Abstract

Additional file 1 : Supplementary Material. Treatment Administration Satisfaction Questionnaire – Intravenous (TASQ-IV). Treatment Administration Satisfaction Questionnaire – Subcutaneous (TASQ-SC). Supplementary Table 1 Participant eligibility criteria. Supplementary Table 2 Participant opinions about the TASQ-IV instructions. Supplementary Table 3 Participant-suggested changes to TASQ-IV instructions. Supplementary Table 4 Participant-suggested changes to TASQ-IV items. Supplementary Table 5 Gaps and participant suggestions for change for TASQ-IV measure overall. Supplementary Table 6 Participant-suggested changes to TASQ-SC instructions.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results